Automated Amino Acid Derivatization and Sample Handling Workflow

Significance of the topic

Automating amino acid derivatization and routine sample handling addresses major bottlenecks in pharmaceutical and biopharmaceutical laboratories: rising sample throughput, operator-dependent variability, and time-consuming manual pipetting. Integrating sample-preparation steps such as precolumn derivatization (OPA/FMOC), sample dilution, and calibration standard preparation directly into the chromatographic injection sequence improves reproducibility, traceability, and operational efficiency while avoiding the complexity and cost of separate liquid‑handling robots.

Objectives and overview

This application note demonstrates a practical injector‑based automation approach that integrates Agilent autosamplers (1260 Infinity III and 1290 Infinity III multisamplers) with Waters Empower CDS via the Waters Instrument Control Framework (WICF). The goal is to implement fully defined injector workflows inside Empower to perform amino acid derivatization (OPA for primary amino acids, FMOC for secondary amino acids), sample dilutions, and calibration standard preparation as part of the injection sequence, enabling high‑throughput, reproducible amino acid analyses without additional external automation hardware.

Methodology

The workflow uses precolumn OPA/FMOC chemistry to derivatize amino acids immediately prior to chromatographic separation. Injector workflows in Empower control reagent addition and incubation steps in the autosampler vial, followed by injection onto an Agilent AdvanceBio AAA LC column (4.6 × 100 mm, 2.7 μm) with a guard column. The method parameters reported include a 1 μL injection volume, 1.5 mL/min flow rate, 40 °C column temperature and a total run time of ca. 18 minutes, with re‑equilibration completed within a sub‑20 minute cycle time.

Derivatization specifics and reagent handling:

• OPA (ortho‑phthalaldehyde) for primary amino acids; FMOC (9‑fluorenylmethyl chloroformate) for secondary amino acids.
• Reagents supplied as ready‑to‑use solutions; OPA and FMOC aliquoted into 100 µL microvial inserts and refrigerated to maximize stability (typical potency 7–10 days after opening).
• Borate buffer replaced every ~3 days; injection diluent prepared from mobile phase A plus phosphoric acid and stored at 4 °C.

Standard and ISTD preparation is described for extended amino acid stocks (EAA) and internal standards (norvaline and sarcosine), with example concentrations used for calibration (commercial Agilent standards and in‑house compounded stocks). Mobile phase A is a borate phosphate buffer (pH 8.2); mobile phase B is acetonitrile:methanol:water (45:45:10 v:v:v).

Used instrumentation

• Agilent 1260 Infinity III Quaternary Pump (G5654A)
• Agilent 1260 Infinity III Multisampler (G5668A) with 100 µL analytical head and 100 µL sample loop (injector workflow capable)
• Agilent 1260 Infinity III Multicolumn Thermostat (G7116B)
• Agilent 1260 Infinity III Diode Array Detector WR (G7115A) with 10 mm bio‑inert flow cell
• Agilent 1260 Infinity III Fluorescence Detector Spectra (G7121B) with 8 µL bio‑inert flow cell (G1321‑60005)
• Agilent AdvanceBio AAA LC column 4.6 × 100 mm, 2.7 μm (p/n 655950‑802) with AdvanceBio AAA guard 4.6 × 5 mm (p/n 820750‑931)
• Waters Empower CDS (WICF 4.0) controlling Agilent instruments via WICF drivers

Main results and discussion

The injector workflow successfully automated OPA/FMOC precolumn derivatization and associated sample handling steps within the Empower sequence. Key performance observations:

• A single analytical run that detects both OPA‑ and FMOC‑derivatized amino acids is achievable by using detector timetable functions to switch detection settings at a determined transition point between lysine (last OPA derivative) and hydroxyproline (first FMOC derivative).
• For DAD, the method uses Signal A (338 nm) for OPA products and Signal B (262 nm) for FMOC products; a timetable switch at ca. 10.6 min was implemented. For FLD, an analogous timetable switches excitation/emission from 340/450 nm to 260/325 nm with appropriate PMT/gain settings.
• Run time is under 20 minutes (including re‑equilibration), supporting moderate to high throughput.
• Chromatographic resolution is excellent: leucine/isoleucine resolution measured at 6.7, substantially exceeding the European Pharmacopoeia requirement of ≥1.5.
• Overlaid replicate injections (six injections shown) demonstrate high repeatability and precision in both UV and fluorescence detectors at reported standard sensitivity (225 pmol/µL AA with 500 pmol/µL ISTD).
• Overall performance—sensitivity, reproducibility and speed—was comparable to conventional injector methods previously published, while offering the advantages of simplified method setup and reduced manual handling.

Benefits and practical applications

• Reduced manual pipetting and fewer operator steps, lowering human error and inter‑operator variability.
• Full integration into Empower CDS provides method traceability and centralized control for regulated environments (pharma/biopharma QC and R&D).
• Cost‑effective automation alternative to standalone liquid‑handling robotics; suitable for labs seeking automation without major infrastructure changes.
• Appropriate for routine amino acid analysis in protein/peptide hydrolysates, amino acid manufacturers’ QC, formulation testing, and other pharmaceutical/biotech workflows requiring high reproducibility and throughput.

Future trends and potential applications

• Wider adoption of CDS‑driven injector workflows to automate other derivatization chemistries and sample‑prep protocols (e.g., small polar metabolites) without additional robotics.
• Integration of online sample clean‑up or SPE coupling to injector workflows for fully automated sample‑to‑result processes.
• Expansion into hyphenated techniques (LC‑MS) where CDS‑controlled injector chemistry could enable consistent derivatization for mass detection, improving quantitation of challenging analytes.
• Further improvements in reagent formats and stability (prealiquoted cartridges or cooled reagent trays) to extend unattended operation times.
• Application of software advances (method templating, automated method transfer, and AI‑assisted method optimization) to further reduce setup time and human oversight.

Conclusion

Injector workflows implemented via Empower CDS and WICF drivers on Agilent InfinityLab LC instrumentation provide a straightforward, reliable route to automate amino acid derivatization, dilution and calibration preparation directly in the autosampler. The approach yields high sensitivity, excellent chromatographic resolution and repeatability in sub‑20 minute runs, reduces manual workload and operator variability, and integrates traceability within the CDS—making it an attractive option for routine amino acid analysis in regulated pharmaceutical and biopharmaceutical laboratories.

Reference

1. Schipperges S. Comparison of Plant‑Based Meat Alternatives and Meat. Agilent Technologies application note, publication number 5994‑5950EN, 2023.
2. Schipperges S. Let Your Autosampler Do Your Pipetting. Agilent Technologies technical overview, publication number 5994‑1704EN, 2020.
3. European Pharmacopoeia 9.0, Section 2.2.56 Amino Acid Analysis.
4. Amino Acid Analysis: How‑To Guide. Agilent Technologies technical overview, publication number 5991‑7694EN, 2017.
5. John W. H.; Robert D. R.; Brian A. B.; Cliff W. Rapid, Accurate, Sensitive, and Reproducible HPLC Analysis of Amino Acids. Agilent Technologies application note, publication number 5980‑1193EN, 2008.
6. William L. Automated Amino Acid Analysis Using an Agilent Poroshell HPH‑C18 Column. Agilent Technologies application note, publication number 5991‑5571EN, 2015/2017.